Artwork

Content provided by Bryn Mawr Communications. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Bryn Mawr Communications or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

AAO ’23: Real-World Faricimab Patterns and Improving GA Assessments

22:13
 
Share
 

Manage episode 386845195 series 2134816
Content provided by Bryn Mawr Communications. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Bryn Mawr Communications or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

The FARETINA-AMD study group assessed approximately 23,000 patients with wet AMD who had received at least one dose of faricimab (Vabysmo, Genentech/Roche). What have they found? Sophie Bakri, MD, summarizes the findings of an IRIS Registry review, which uncovered data about who has been dosed with faricimab, how frequently extended dosing intervals have been achieved, and whether real-world safety issues have cropped up.

And Karl Csaky, MD, PhD, offers a glimpse into the future of geographic atrophy care. Are any budding technologies better able to assess structure and function in GA patients? Keep it here to find out.

This Editorially independent content is supported with advertising.

  continue reading

162 episodes

Artwork
iconShare
 
Manage episode 386845195 series 2134816
Content provided by Bryn Mawr Communications. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Bryn Mawr Communications or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

The FARETINA-AMD study group assessed approximately 23,000 patients with wet AMD who had received at least one dose of faricimab (Vabysmo, Genentech/Roche). What have they found? Sophie Bakri, MD, summarizes the findings of an IRIS Registry review, which uncovered data about who has been dosed with faricimab, how frequently extended dosing intervals have been achieved, and whether real-world safety issues have cropped up.

And Karl Csaky, MD, PhD, offers a glimpse into the future of geographic atrophy care. Are any budding technologies better able to assess structure and function in GA patients? Keep it here to find out.

This Editorially independent content is supported with advertising.

  continue reading

162 episodes

Все серии

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide